3B Pharmaceuticals (3BP) is a German biotechnology company developing radiopharmaceutical drugs and diagnostics for oncology indications. Credit: stevepb from Pixabay.

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology.

The deal provides Novartis with exclusive rights across the globe to create and commercialise therapeutic and imaging solutions for 3BP’s entire FAP-targeting peptide technology, including FAP-2286.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments. Tiered royalties on net sales are also included in the deal.

3BP continues to hold specific rights to develop its FAP-targeting imaging technology for diagnostic applications.

FAP-2286 is being investigated as a peptide-targeted radionuclide therapy. It is capable of targeting FAP, a significant theranostic target with expression across various types of cancers.

FAP-2286 marks the first peptide-targeted radioligand therapy aiming at FAP to enter clinical development, along with the respective imaging agent.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The therapy candidate is currently under evaluation in the Phase l LuMIERE clinical trial.

3BP nuclear medicine and imaging head Dr Christiane Smerling stated: “We believe the new agreement with Novartis is an ideal partnership for the further clinical development of FAP-2286 for the benefit of patients with many different types of cancer.”

In 2019, 3BP reached a licence and collaboration deal with Clovis Oncology to support the development of a peptide-targeted radiotherapy and imaging agent targeting FAP.